2-氯-1-丙基-1H-苯并咪唑 | 80841-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-氯-1-丙基-1H-苯并咪唑
• 英文名称: 2-chloro-1-propyl-1H-benzo[d]imidazole
• 英文别名: 2-chloro-1-n-propylbenzimidazole；2-chloro-1-propylbenzimidazole
• CAS: 80841-35-6
• 化学式: C₁₀H₁₁ClN₂
• 分子量: 194.664
• InChiKey: GSCJWQVBZGODGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-氯-1-丙基-1H-苯并咪唑 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 10-Propyl-2,10-dihydro-benzo[4,5]imidazo[2,1-c][1,2,4]triazine-3,4-dione
  参考文献：
  名称：

  [1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives:  A New Class of Selective Aldose Reductase Inhibitors

  摘要：

  Acetic acid derivatives of [1,2,4]triazino[4,3-alpha ]benzimidazole (TBI) were synthesized and tested in vitro and in vivo as a novel class of aldose reductase (ALR2) inhibitors. Compound 3, (10-benzyl[1,2,4]triazino[4,3-alpha ]benzimidazol-3,4(10H)-dion-2-yl)acetic acid, displayed the highest inhibitory activity (IC50 = 0.36 muM) and was found to be effective in preventing cataract development in severely galactosemic rats when administered as an eyedrop solution. All the compounds investigated were selective for ALR2, since none of them inhibited appreciably aldehyde reductase, sorbitol dehydrogenase, or glutathione reductase. The activity of 3 was lowered by inserting various substituents on the pendant phenyl ring, by shifting the acetic acid moiety from the 2 to the 3 position of the TBI nucleus, or by cleaving the TBI system to yield benzimidazolylidenehydrazines as open-chain analogues. A three-dimensional model of human ALR2 was built, taking into account the conformational. changes induced by the binding of inhibitors such as zopolrestat, to simulate the docking of 3 into the enzyme active site. The theoretical binding mode of 3 was fully consistent with the structure-activity relationships in the TBI series and will guide the design of novel ALR2 inhibitors.

  DOI：

  10.1021/jm0109210
• 作为产物：
  描述：

  2-氯苯并咪唑 在 偶氮二异丁腈 、 三正丁基氢锡 、 sodium hydride 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 9.0h， 生成 2-氯-1-丙基-1H-苯并咪唑
  参考文献：
  名称：

  使用固相合成进行芳香均质取代

  摘要：

  固相合成已被用于用苯并咪唑前体进行分子内芳香族均质取代。该方案将自由基前体通过自由基离去基团（在芳香族均质取代中）连接到树脂上。当自由基反应完成时，离去基团，未改变的起始原料和还原的未酰化产物仍保留在树脂上，这有利于环化产物的容易分离。在固相自由基反应中使用聚焦微波辐射的新方法大大缩短了反应时间。氢化三丁基锗氢化物已用于取代自由基反应中有毒且麻烦的氢化三丁基锡。

  DOI：

  10.1016/j.tet.2006.02.071

文献信息

• New 2-Piperazinylbenzimidazole Derivatives as 5-HT₃ Antagonists. Synthesis and Pharmacological Evaluation
  作者：Aurelio Orjales、Ramón Mosquera、Luis Labeaga、Rosa Rodes

  DOI：10.1021/jm960442e

  日期：1997.2.1

  of 2-piperazinylbenzimidazole derivatives were prepared and evaluated as 5-HT3 receptor antagonists. Their 5-HT3 receptor affinities were evaluated by radioligand binding assays, and their abilities to inhibit the 5-HT-induced Bezold-Jarisch reflex in anesthetized rats were determined. Compound 7e (lerisetron, pKi = 9.2) exhibited higher affinity for the 5-HT3 receptor than did tropisetron and granisetron

  制备了一系列2-哌嗪基苯并咪唑衍生物，并将其评价为5-HT 3受体拮抗剂。通过放射性配体结合测定法评估了它们的5-HT3受体亲和力，并确定了它们在麻醉大鼠中抑制5-HT诱导的Bezold-Jarisch反射的能力。化合物7e（lerisetron，pKi = 9.2）对5-HT3受体的亲和力高于tropisetron和granisetron，而化合物7q（pKi = 7.5）对该受体的亲和力很低，表明苯并咪唑的N1原子被取代环对于亲和力和活性至关重要。还讨论了不同位置的多个取代基对苯并咪唑芳环的取代作用。建立了所研究化合物的5-HT3拮抗活性与芳香环上取代位置的强相关性。因此，尽管4-甲氧基衍生物7m显示出对5-HT 3受体的弱亲和力（pKi ＝ 6.7），但是7-甲氧基衍生物7n显示出最高的亲和力（pKi ＝ 9.4）。化合物7e和7n作为癌症化疗和放疗引起的恶心和呕吐的治疗药物，目前正在进一步研究中。
• Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-antihistaminic agents
  作者：Ryuichi Iemura、Tsuneo Kawashima、Toshikazu Fukuda、Keizo Ito、Goro Tsukamoto

  DOI：10.1021/jm00157a010

  日期：1986.7

  A series of 2-(4-substituted-1-(homo)piperazinyl)benzimidazoles was prepared and tested for H1-antihistaminic activity in vitro and in vivo. Most of the compounds showed antihistaminic activity and some of the 1-[2-(substituted-oxy)ethyl] derivatives exhibited potent activity. In a structure-activity comparison it was found that the oxygen atom in the 2-(substituted-oxy)ethyl group at the 1-position

  制备了一系列的2-（4-取代的-1-（高）哌嗪基）苯并咪唑，并在体内和体外测试了H1-抗组胺活性。大多数化合物显示出抗组胺活性，而某些1- [2-（取代-氧基）乙基]衍生物则显示出有效的活性。在结构活性比较中，发现苯并咪唑核的1-位上的2-（取代-氧）乙基中的氧原子对于有效的抗组胺活性，特别是在体内具有重要作用。最有效的化合物之一1-（2-乙氧基乙基）-2-（4-甲基-1-高哌嗪基）苯并咪唑（69）的体内H1抗组胺活性比马来酸氯苯那敏高39倍，因此被选作临床评估。
• NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Buckman Brad

  公开号：US20110081315A1

  公开（公告）日：2011-04-07

  The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供了一般式I、Ia、II、III、IV、V、VI-1、VI-2、VII、VIII、IX、X、XI和XII的化合物，以及包括药物组合物在内的组合物。本实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要该化合物或组合物的个体施用有效量的该化合物或组合物。
• [EN] 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES
  申请人：——

  公开号：WO1981003022A1

  公开（公告）日：1981-10-29

  (EN) 2-(1-piperazinyl)-4-pyrimidinamine derivatives, acid addition salts thereof, processes for their preparation, methods of using the derivatives and pharmaceutical compositions of the derivatives. The derivatives are useful for treating hypertension in a mammal. (FR) Derives a base de 2-(1-piperaziayl)-4-pyrinidinamine, leurs sels d'addition acides, procede pour leur preparation, procede d'utilisation de ces derives et composition pharmaceutique les contenant. Les derives sont utiles pour le traitement de l'hypertension chez les mammiferes.

  (EN) 2-(1-吡咯烷基)-4-吡啶胺衍生物及其酸性添加盐，制备该衍生物的方法，使用该衍生物的方法及药物合成。这些衍生物可用于治疗哺乳动物的高血压。 (FR) 以2-(1-吡咯烷基)-4-吡啶胺为基础的衍生物及其酸性添加盐，制备它们的方法，使用该衍生物的方法及药物合成。这些衍生物可用于治疗哺乳动物的高血压。
• Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903
  作者：Swagat H. Sharma、Juan Lorenzo Pablo、Monica Suarez Montesinos、Anna Greka、Corey R. Hopkins

  DOI：10.1016/j.bmcl.2018.12.007

  日期：2019.1

  The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.